{"disease":{"id":"anti-angiogenesis","name":"anti angiogenesis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06475755","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":178,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT05460195","title":"Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}